Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $2.1B | $2.1B | $2.0B | $2.0B | $2.1B | $2.3B | $1.9B | $1.5B | $1.5B | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.2B | $1.1B | $1.0B | $893M | $650M | $466M |
| Bruttoergebnis | $1.3B | $1.3B | $967M | $1.2B | $1.4B | $1.5B | $1.2B | $1.0B | $1.0B | $923M | $845M | $827M | $865M | $815M | $824M | $750M | $716M | $667M | $600M | $434M | $325M |
| Bruttomarge % | 61.8% | 61.8% | 48.9% | 62.8% | 64.6% | 64.4% | 65.9% | 65.9% | 66.6% | 65.1% | 63.1% | 64.5% | 64.3% | 62.6% | 65.7% | 64.1% | 65.8% | 66.1% | 67.2% | 66.7% | 69.7% |
| Betriebsergebnis (EBIT) | $541M | $520M | $98M | $410M | $531M | $630M | $386M | ($26M) | $267M | $153M | $99M | $179M | $162M | $63M | $170M | $100M | $189M | $180M | $146M | $83M | $101M |
| Operative Marge % | 25.8% | 24.9% | 4.9% | 20.9% | 24.8% | 28.0% | 20.7% | -1.7% | 17.8% | 10.8% | 7.4% | 14.0% | 12.0% | 4.9% | 13.5% | 8.5% | 17.3% | 17.8% | 16.3% | 12.8% | 21.6% |
| Jahresüberschuss | $409M | $425M | $84M | $341M | $423M | $513M | $359M | ($41M) | $190M | $40M | $80M | $130M | $116M | $69M | $130M | $96M | $144M | $138M | $89M | $50M | $71M |
| Nettomarge % | 19.5% | 20.3% | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% | -2.7% | 12.7% | 2.9% | 6.0% | 10.2% | 8.6% | 5.3% | 10.3% | 8.2% | 13.3% | 13.6% | 10.0% | 7.7% | 15.1% |
| EBITDA | — | $717M | $368M | $689M | $779M | $895M | $716M | $228M | $499M | $381M | $309M | $365M | $360M | $268M | $366M | $289M | $344M | $322M | $263M | $195M | $140M |
| Ergebnis je Aktie (EPS) | $1.95 | $2.04 | $0.38 | $1.57 | $1.90 | $2.28 | $1.58 | $-0.19 | $0.82 | $0.17 | $0.35 | $0.57 | $0.50 | $0.30 | $0.56 | $0.42 | $0.62 | $0.67 | $0.45 | $0.30 | $0.48 |
| Ausstehende Aktien (Mio.) | — | 208M | 218M | 217M | 223M | 225M | 227M | 220M | 233M | 233M | 230M | 228M | 233M | 233M | 232M | 230M | 232M | 206M | 197M | 169M | 148M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für QGEN. /companies/us/QGEN
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms